TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :\>~* HIV-1 infected\>~* CD4 count fewer than 300 cells/mm3 \>~* Viral load test result\>~* Absolute Neutrophil Count at least 750mm3 \>~* Hemoglobin at least 7.5 g/dL\>~* Platelet count at least 50,000/mm3\>~* Calculated creatinine clearance at least 60 mL/min\>~* A , A, and alkaline phosphatase \<= 5 times upper limit of normal\>~* total bilirubin \<= 2.5 times upper limit of normal\>~* Karnofsky performance score of 70 or higher\>~* Plans to stay in the area for the duration of the study\>~* Agrees to use acceptable forms of contraception for the duration of the study\>~Exclusion Criteria:\>~* More than 7 days exposure to ARVs (except for single-dose NVP or ZDV for any period for the purpose of pMTCT)\>~* Acute therapy for serious medical illnesses within 14 days prior to study entry\>~* Certain abnormal laboratory values\>~* Radiation therapy or chemotherapy within 45 days prior to study entry. \>~* Any immunomodulator, HIV vaccine, or other investigational therapy within 30 days prior to study entry. \>~* Current alcohol or drug abuse that, in the opinion of the site investigator, would interfere with study participation\>~* Inflamed pancreas within 3 years prior to study entry\>~* Allergy/sensitivity to any of the study drugs or their formulations\>~* Heart rate less than 40 beats/min\>~* History of untreated, active second- or third-degree heart block\>~* Currently detained in jail or for treatment of a psychiatric or physical illness\>~* Vomiting or inability to swallow medications\>~* Pregnancy\>

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZDV/3TC+EFV (Type: EXPERIMENTAL): ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
- ddI+FTC+ATV (Type: EXPERIMENTAL): ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
- TDF/FTC+EFV (Type: EXPERIMENTAL): TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Type 2 Diabetes Mellitus patients (age ≥18yr) drug naive or treated with metformin monotherapy (≥1500 mg/day or individually maximally tolerated dose) for at least 12 weeks with a Hemoglobin A1c between ≥ 7.5% and ≤ 11.0% at screening.~* Fasting plasma glucose ≤13.3mmol/L(≤240mg/dL) at screening.~* Patients with documented history of Coronary Heart Disease (CHD) or High cardiovascular(CV) risk.~* History of CHD, defined as previous myocardial infarction or unstable/stable angina.~* High CV risk, defined as male or female (age\> 50 yr), combined with at least one of these risk factors as below: family history of cardiovascular disease, history of hypertension, smoking, dyslipidemia, or protein urine.~* Already treated with Aspirin or should start Aspirin treatment at physician's discretion.~Exclusion criteria:~* Diagnosis of type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes.~* Previous treatment with any Dipeptidyl Peptidase -4 inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonists within 1 year of screening;~* Any contraindication of Aspirin, Dipeptidyl Peptidase- 4 inhibitor and Alpha-glucosidase inhibitor.~* Clinically apparent liver disease or moderate /severe renal impairment or end-stage renal disease~* Unstable CV disorder including heart failure (New York Heart Association class III or IV), refractory angina, uncontrolled arrhythmias, and severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥105 mmHg).~* Acute coronary syndrome event within 6 month before randomization~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alogliptin (Type: EXPERIMENTAL): Single dose of alogliptin once daily for 16 weeks
- Acarbose (Type: ACTIVE_COMPARATOR): Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abilify as an Adjunctive Treatment for Refractory Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients between the ages of 18 and 70.~* Patients with a principal Diagnostic and Statistical Manual fourth edition (DSM-IV) diagnosis of Major Depressive Disorder, unipolar, nonpsychotic type~* Patients with a total of 14 or higher on the 17-item Hamilton Depression Scale at baseline~* Patients who have had treatment with an SSRI at an adequate dose (see Table for a minimum of 6 weeks (i.e. 6 wks at the dose defined as adequate in Table 2)~* Patients who agree to use acceptable method of birth control throughout the study~Exclusion Criteria:~* Patients with any of the following DSM-IV diagnoses: Delirium, Dementia, Amnestic, or other Cognitive Disorders. Bipolar Disorder or cyclothymia, Schizophrenia, Delusional (Paranoid) Disorders and Psychotic Disorders not elsewhere classified, Severe Borderline Personality Disorder, Anorexia Nervosa, or Bulimia.~* Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence on any drug, including alcohol.~* Patients who are pregnant or nursing women.~* Patients who would pose a serious risk for suicide during the course of the study, as evidenced by one of the following: (a) report of having a specific plan for killing themselves, (b) a score of 3 or higher on the Hamilton Depression Rating Scale item #3 as rated by the treating clinician at Week 0, or (c) a suicide attempt within the last 6 months which required medical attention, such as an emergency room visit or which is considered by the treating physician to have been possibly life threatening~* Patients with unstable medical conditions such as untreated or uncontrolled hyperthyroidism, hypothyroidism, hypertension (defined as blood pressure\>150/90), cardiovascular disease, diabetes, HIV (by report of patient).~* Patients with a history of seizures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): Aripiprazole 5 to 30 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sublingual Immunotherapy in Peanut-allergic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Peanut IgE \> 7kU/L (\> 2kU/L for children aged 2 years and under) AND~* History of significant clinical symptoms within 60 minutes after the ingestion of peanuts.~Exclusion Criteria:~* History of severe life-threatening anaphylaxis to peanut, OR~* Medical history that would prevent a DBPCFC to peanut, OR~* Subjects with wheat or oat allergy (which are used in the placebo), OR~* Unable to cooperate with challenge procedures, OR~* Unable to be reached by telephone for follow-up

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Blinded Peanut SLIT (Type: ACTIVE_COMPARATOR): Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
- Blinded Placebo SLIT (Type: PLACEBO_COMPARATOR): Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
- Ext. maint. open label peanut SLIT (Type: OTHER): After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
- Early unblinded peanut SLIT (Type: OTHER): Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
- Pilot peanut SLIT rollover cohort (Type: OTHER): Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Cocaine Vaccine: Human Laboratory Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets DSM-IV criteria for current cocaine dependence. The volunteer may meet criteria for other substance abuse, but not dependence (other than nicotine).~2. Primary route of cocaine administration is smoking.~3. Age 21-45.~4. Females must be surgically sterilized or post- menopausal~5. Able to give informed consent, and comply with study procedures.~Exclusion Criteria:~1. Dependence on substances other than cocaine or nicotine.~2. Judged to be noncompliant with study protocol.~3. History of autoimmune disease, immune deficiency or hypersensitivity to other vaccines. An HIV test must be negative.~4. Currently uses drugs intravenously~5. Currently taking any psychotropic medication~6. Laboratory tests that are clinically unacceptable to the study physician (BP \> 140/90; BUN, creatinine, LFTs \> 1.5 ULN; hematocrit \< 34 for women, \< 36 for men)~7. Blood or blood products given in the three months prior to vaccination~8. Other vaccines, including flu vaccine, given within 30 days of screening.~9. Ongoing active infection~10. Currently taking immunosuppressives -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Low dose Vaccine (Type: EXPERIMENTAL): All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
- High Dose Vaccine (Type: EXPERIMENTAL): All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed malignancy (whose pain is judged by the investigator to be caused by the malignancy), or patients with other life-threatening/terminal disease whose pain requires treatment with strong opioid analgesia~* requiring treatment of pain with a strong opioid and who are expected to continue to require treatment with a strong opioid for the duration of the study~* receiving a stable dose of immediate-release oral morphine or sustained-release morphine (minimum daily dose of morphine is 30 mg/day) for at least 48 hours immediately prior to entry into the study~Exclusion Criteria:~* Patients with a history of allergy or hypersensitivity to fentanyl or morphine~* have active skin disease that precludes application of Durogesic® or which may affect the absorption of fentanyl~* have a clinical condition that in the investigator's judgment prevents participation in the study~* have participated in any other drug trial relating to pain control within one month of study entry~* currently participating in any other study or research project which would interfere with this trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Females Age 9 To 15 Years~* Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study~* No Fevers 24 Hours Prior To The First Injection~Exclusion Criteria:~* Participant Had Received A Prior Vaccination With A HPV Vaccine~* Participant Has Allergies To Vaccine Component Including Aluminum And Yeast~* Participant Has (Human Immunodeficiency Virus) HIV Infection~* Participant Is Immunocompromised~* Participant Received Or Plans To Receive Blood-Derived Product Within 6 Months Prior To The First Injection~* Participant Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To The First Injection

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18) (Type: EXPERIMENTAL): Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects of any race, aged 18 to 50 years inclusive~* Subjects with a past history of acne and with moderate to severe facial atrophic acne scars~Exclusion Criteria:~* Subjects with active inflammatory acne lesions~* Subjects with hypertrophic acne scars

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Differin 0.3% (Type: EXPERIMENTAL): Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented history of seasonal allergic rhinitis symptoms that flare up during the study season~* Patient is a nonsmoker~* Patient is in good general health~Exclusion Criteria:~* Patient is hospitalized~* Patient is a woman who is less than 8 weeks postpartum or is breast-feeding~* Patient intends to move or vacation away during the study~* Patient has had any major surgery within 4 weeks of study start~* Patient is a current or past abuser of alcohol or illicit drugs~* Patient has been treated in an emergency room for asthma in the past month~* Patient had an upper respiratory infection with in 3 weeks prior to study start~* Patient has any active pulmonary disorder other than asthma

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): montelukast/loratadine
- 2 (Type: EXPERIMENTAL): loratadine
- 3 (Type: EXPERIMENTAL): montelukast
- 4 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Males and females ages 18-69 who are of Hispanic origin~* Symptoms of GERD, defined as heartburn at least 2 times a week on average over the last 3 months~Exclusion Criteria:~* Female patients who are pregnant or breastfeeding~* Known intolerance or lack of response to Proton Pump Inhibitors (PPIs) such as Nexium, Prevacid, or Protonix~* Current or relevant history of non-healed ulcers, stomach surgery, or esophageal surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term, Open Label Atomoxetine Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 6 years old but less than 18 years old when enrolled in first atomoxetine study~* Must meet the study criteria for ADHD~* Must be willing to have blood drawn and to complete other test required for this study~Exclusion Criteria:~* allergic to more than 1 kind of medicine or have had multiple bad reactions to any drug~* taking certain medicines that could interact with atomoxetine~* plan to move too far away from a doctor participating in this study in the next 5 years~* current or past history of any of the following: alcohol or drug abuse within the past 3 months, bipolar I or II disorder, high blood pressure, organic brain disease or seizures, psychosis, other disorders or conditions diagnosed by a doctor that might make you unsuitable to participate in this study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Biomarker Study (BMS-936558)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Women and men ≥ 18 years of age.~* Histologic confirmation of renal cell carcinoma with a clear cell component.~* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).~* Tumor sites that can be accessed for repeat biopsies at acceptable clinical risk.~* Previously treated subjects must have failed at least 1 prior anti-angiogenic agent and can have a maximum of 3 prior systemic treatments for renal cell cancer.~* Subjects in the treatment naive arm cannot have received prior systemic therapy for their renal cell carcinoma.~Exclusion Criteria:~* Active or progressing brain metastases.~* Active concomitant.~* Active or history of autoimmune disease.~* Active use of systemic corticosteroids.~* Prior therapy with Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4), anti Programmed death-1 (anti-PD1), anti Programmed death ligand 1 (anti-PD-L1), anti Programmed death ligand 2 (anti-PD-L2), anti-CD137, anti-CD40, anti-OX40 antibodies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 2: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 3: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 4: BMS-936558 (Type: EXPERIMENTAL): (treatment naive)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children who undergo an appendectomy for perforated appendicitis. (Appendicitis: Diagnosis is made intraoperatively by the surgeon. Diagnosis Method: The visualization of a gross defect in the appendiceal wall or the presence of intraperitoneal stool or a fecalith at the time of operation.)~Exclusion Criteria:~* Patients presenting with simple or gangrenous appendicitis~* Patients with a history of iodine sensitivity, thyroid disease or renal disease~* Patients undergoing interval or incidental appendectomy~* Patients/parents/legal guardians who are both non-English and non-Spanish speaking

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Povidone-iodine irrigation (Type: EXPERIMENTAL): None
- No irrigation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete